Epidemiology of CYP3A4-mediated clopidogrel drug-drug interactions and their clinical consequences

Cardiovascular Therapeutics

Volumn 31, Issue 6, 2013, Pages 344-351

  Tirkkonen, Tuire ^a,b   Heikkilä, Pekka ^c   Vahlberg, Tero ^a   Huupponen, Risto ^a,b   Laine, Kari ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c StatFinn Ltd   (Finland)

Author keywords

Atorvastatin; Clopidogrel; CYP3A4; Drug drug interaction

Indexed keywords

ATORVASTATIN; CARBAMAZEPINE; CLOPIDOGREL; CYTOCHROME P450 3A4; DILTIAZEM; FLUCONAZOLE; PHENYTOIN;

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; BLEEDING; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HAZARD RATIO; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; SURVIVAL; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ATORVASTATIN; CLOPIDOGREL; CYP3A4; DRUG-DRUG INTERACTION;

AGED; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PYRROLES; TICLOPIDINE;

EID: 84888376623     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12028     Document Type: Article

References (30)

1. European Medicines Agency (EMEA). Plavix: Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000174/WC500042189.pdf
2. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38:92-99.
3. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003;31:53-59.
4. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 2003;107:32-37.
5. Muller I, Besta F, Schulz C, Li Z, Massberg S, Gawaz M. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 2003;108:2195-2197.
6. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004;109:1335-1338.
7. Gorchakova O, von Beckerath N, Gawaz M, Mocz A, Joost A, Schomig A, Kastrati A. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 2004;25:1898-1902.
8. Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: Results from the interaction study. Arch Intern Med 2004;164:2051-2057.
9. Wenaweser P, Eshtehardi P, Abrecht L, et al. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial. Thromb Haemost 2010;104:554-562.
10. Park Y, Jeong YH, Tantry US, et al. Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. Eur Heart J 2012;33:2151-2162.
11. Trenk D, Hochholzer W, Frundi D, et al. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost 2008;99:174-181.
12. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, Topol EJ. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003;108:921-924.
13. Saw J, Brennan DM, Steinhubl SR, Bhatt DL, Mak KH, Fox K, Topol EJ. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 2007;50:291-295.
14. Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003;92:285-288.
15. Mc Donnell CG, Harte S, O'Driscoll J, O'Loughlin C, Van Pelt FN, Shorten GD. The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. Anaesthesia 2003; 58:899-904.
16. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735-741.
17. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004;109:166-171.
18. Steinhubl SR. Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines. Circulation 2010;121:481-483.
19. PubMed. US National Library of Medicine National Institutes of Health. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi
20. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008;167:492-499.
21. Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006;80:486-501.
22. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002;87:1451-1458.
23. Luoma PV, Myllyla VV, Sotaniemi EA, Lehtinen IA, Hokkanen EJ. Plasma high-density lipoprotein cholesterol in epileptics treated with various anticonvulsants. Eur Neurol 1980;19:67-72.
24. Nikolaos T, Stylianos G, Chryssoula N, et al. The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit 2004; 10:MT50-MT52.
25. Mukherjee D, Kline-Rogers E, Fang J, Munir K, Eagle KA. Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart 2005;91:23-26.
26. Lotfi A, Schweiger MJ, Giugliano GR, Murphy SA, Cannon CP. TIMI 22 Investigators. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients-a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. Am Heart J 2008;155:954-958.
27. Paciaroni M, Bogousslavsky J. Statins and stroke prevention. Expert Rev Cardiovasc Ther 2009;7:1231-1243.
28. Fernando H, Dart AM, Peter K, Shaw JA. Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. Thromb Haemost 2011;105:933-944.
29. Schror K. Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997;23:349-356.
30. Damman P, Woudstra P, Kuijt WJ, de Winter RJ, James SK. P2Y12 platelet inhibition in clinical practice. J Thromb Thrombolysis 2012;33:143-153.